


PRODUCT INFORMATION



Mitiglinide (calcium salt)

Item No. 30693

CAS Registry No.: 145525-41-3
Formal Name: (αS,3aR,7aS)-octahydro-γ-oxo-α-(phenylmethyl)-2H-isoindole-2-butanoic acid, hemicalcium salt
Synonyms: KAD-1229, S21403
MF: C₁₉H₂₄NO₃ • 1/2Ca
FW: 334.4
Purity: ≥98% (mixture of isomers)
UV/Vis.: λ_{max}: 239 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Mitiglinide (calcium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the mitiglinide (calcium salt) in the solvent of choice, which should be purged with an inert gas. Mitiglinide (calcium salt) is slightly soluble in DMSO, dimethyl formamide, methanol, and chloroform.

Description

Mitiglinide is an inhibitor of sulfonylurea receptor 1 (SUR1) linked to ATP-sensitive potassium channel K_{ir}6.2 (IC₅₀ = 4 nM).¹ It is selective for SUR1/K_{ir}6.2 over SUR2A/K_{ir}6.2 and SUR2B/K_{ir}6.2 channels (IC₅₀s = 3 and 5 μM, respectively). Mitiglinide induces insulin release in HIT-T15 insulinoma cells and isolated mouse pancreatic islets when used at a concentration of 100 μM.² Oral administration of mitiglinide (1, 3, and 10 mg/kg) increases postprandial plasma insulin levels and inhibits postprandial increases in plasma glucose levels in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).³

References

1. Reimann, F., Proks, P., and Ashcroft, F.M. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. *Br. J. Pharmacol.* **132**(7), 1542-1548 (2001).
2. Ohnota, H., Koizumi, T., Tsutsumi, N., *et al.* Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: Comparison of effects between KAD-1229 and gliclazide. *J. Pharmacol. Exp. Ther.* **269**(2), 489-495 (1994).
3. Ohnota, H., Kitamura, T., Kinukawa, M., *et al.* A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. *Jpn. J. Pharmacol.* **71**(4), 315-323 (1996).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/31/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM